Tan Nuopei, Li Yan, Ying Jianming, Chen Wanqing
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Transl Int Med. 2024 Nov 6;12(5):452-465. doi: 10.1515/jtim-2024-0019. eCollection 2024 Nov.
Histological transformation from lung adenocarcinoma (ADC) to small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC), squamous cell carcinoma (SCC), and sarcomatoid carcinoma (PSC) after targeted therapies is recognized as a mechanism of resistance in ADC treatments. Patients with transformed lung cancer typically experience a poor prognosis and short survival time. However, effective treatment options for these patients are currently lacking. Therefore, understanding the mechanisms underlying histological transformation is crucial for the development of effective therapies. Hypotheses including intratumoral heterogeneity, cancer stem cells, and alteration of suppressor genes have been proposed to explain the mechanism of histological transformation. In this review, we provide a comprehensive overview of the known molecular features and signaling pathways of transformed tumors, and summarized potential therapies based on previous findings.
在靶向治疗后,肺腺癌(ADC)向小细胞肺癌(SCLC)、大细胞神经内分泌癌(LCNEC)、鳞状细胞癌(SCC)和肉瘤样癌(PSC)的组织学转化被认为是ADC治疗中的一种耐药机制。肺癌转化患者通常预后较差且生存时间短。然而,目前这些患者缺乏有效的治疗选择。因此,了解组织学转化的潜在机制对于开发有效治疗方法至关重要。包括肿瘤内异质性、癌症干细胞和抑癌基因改变等假说已被提出以解释组织学转化的机制。在本综述中,我们全面概述了转化肿瘤的已知分子特征和信号通路,并根据先前的研究结果总结了潜在的治疗方法。